My watch list
my.chemeurope.com  
Login  

[In Depth] As Ebola wanes, trials jockey for patients

The Ebola epidemic in West Africa has caused enormous suffering, but scientists also see it as a chance to test experimental therapies that could save lives in the future. With declining case numbers, however, it is becoming less likely that all the drug tests will reach a conclusion. Now, scientists are debating whether some trials should be stopped so that tests of more promising therapies that have only now become available have a better chance of reaching a conclusion. An expert panel at the World Health Organization has given ZMapp and TKM-Ebola highest priority but in a recent meeting did not call for ongoing studies of favipiravir and convalescent blood to be stopped. The experts did convince a group of Italian doctors to test ZMapp instead of the heart drug amiodarone and criticized an interferon trial that has now started in Guinea. Author: Kai Kupferschmidt

Authors:   Kai Kupferschmidt
Journal:   Science
Volume:   348
edition:   6230
Year:   2015
Pages:   20
DOI:   10.1126/science.348.6230.20
Publication date:   03-Apr-2015
Facts, background information, dossiers
More about Science International / AAAS
  • News

    It's Not an Illusion

    Researchers have developed a compound that can transform near-infrared light into broadband white-light, offering a cheap, efficient means to produce visible light. The emitted light is also exceedingly directional, a desirable quality for devices like microscopes that require high spatial ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE